Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Proof of Concept Study to Evaluate the Dose Response for the Systemic Benefit Risk Ratio of Inhaled Fluticasone Propionate in Chronic Obstructive Pulmonary Disease

This study has been completed.
Information provided by:
University of Dundee Identifier:
First received: October 14, 2009
Last updated: NA
Last verified: October 2009
History: No changes posted

Chronic Obstructive Pulmonary Disease (COPD) is a major worldwide problem.Steroids inhalers are now an established treatment for COPD. Inhaled steroids can have a number of bad effects including suppression of the adrenal glands because of absorption. A previous study in patients with COPD.

C-reactive Protein (CRP) is a peptide produced in the liver in response to inflammation. Elevated circulating levels of CRP are associated with heart conditions. High levels of CRP have also been found in patients with COPD. In some studies, steroid inhalers have reduced CRP levels, and that of other inflammatory mediators, in patients with COPD. It is unknown whether this reflects a reduction in lung inflammation or an effect of systemically absorbed corticosteroid.

It is proposed to investigate the link between inhaled corticosteroid and serum CRP, lung inflammation (measured by exhaled nitric oxide) and systemic absorption of steroids.

Condition Intervention Phase
Drug: Fluticasone propionate
Drug: Placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Proof of Concept Study to Evaluate the Dose Response for the Systemic Benefit Risk Ratio of Inhaled Fluticasone Propionate in Chronic Obstructive Pulmonary Disease

Resource links provided by NLM:

Further study details as provided by University of Dundee:

Primary Outcome Measures:
  • CRP [ Time Frame: 4 weeks ]

Secondary Outcome Measures:
  • Alveolar nitric oxide [ Time Frame: 4 weeks ]
  • OUCC [ Time Frame: 4 weeks ]

Enrollment: 18
Study Start Date: October 2006
Study Completion Date: November 2008
Primary Completion Date: November 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Inhaled corticosteroid Drug: Fluticasone propionate
Placebo Comparator: Placebo control Drug: Placebo


Ages Eligible for Study:   Child, Adult, Senior

Inclusion Criteria:

  • Current or ex-smokers
  • Aged over 50years
  • FEV1/FVC ratio <0.7
  • FEV1<80% predicted
  • Improvement in FEV1 following short acting beta-agonist not greater than 15% and 200ml.

Exclusion Criteria:

  • Diagnosis of asthma, bronchiectasis or ABPA
  • Inability to perform study procedures or give informed consent
  • Known sensitivity to trial medications
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Peter Alan Williamson, University of Dundee Identifier: NCT00995475     History of Changes
Other Study ID Numbers: MEN001
Study First Received: October 14, 2009
Last Updated: October 14, 2009

Additional relevant MeSH terms:
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases
Anti-Inflammatory Agents
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Dermatologic Agents
Anti-Allergic Agents processed this record on May 22, 2017